Transcriptomics data on dual G9a and DNMT inhibition, using the proprietary drug CM-272, in the MO4 melanoma mouse model (DATASET 1) - INHIBITING HISTONE AND DNA METHYLATION IMPROVES CANCER VACCINATION IN AN EXPERIMENTAL MODEL OF MELANOMA. De Beck, et al.
Description
This dataset contains transcriptomics data on dual G9a and DNMT inhibition in the MO4 melanoma mouse model, related to the original research manuscript: INHIBITING HISTONE AND DNA METHYLATION IMPROVES CANCER VACCINATION IN AN EXPERIMENTAL MODEL OF MELANOMA. De Beck, et al. - under review. (a) Multiplex gene expression analysis on ex vivo tumor tissue. Tumors of MO4 tumor-bearing mice subjected to the CM-272 treatment regimen were resected at 706.9±193.8 mm3 tumor volume and subjected to multiplex gene expression analysis using the nCounter PanCancer Mouse Immune Profiling Panel on the nCounter MAX Analysis System. Sample annotation is provided in the annotation file. (b) MO4 cells were treated for 24 hours with 1µM CM-272 or vehicle before RNA was extracted for sequencing. Samples are identified as follows: vehicle condition (RNA-LienDB-A1_S37 and RNA-LienDB-A3_S39) or CM-272 treatment condition (RNA-LienDB-A2_S38 and RNA-LienDB-A4_S40). ---- Dataset completed at "Transcriptomics data on dual G9a and DNMT inhibition, using the proprietary drug CM-272, in the MO4 melanoma mouse model (DATASET 2) - INHIBITING HISTONE AND DNA METHYLATION IMPROVES CANCER VACCINATION IN AN EXPERIMENTAL MODEL OF MELANOMA. De Beck, et al.
Files
Steps to reproduce
Details on data analysis can be found in the original article this dataset refers to.